Mucosal leishmaniasis ("espundia") responsive to low dose of N-methyl glucamine (Glucantime ®) in Rio de Janeiro, Brazil
Open Access
- 1 December 2000
- journal article
- clinical trial
- Published by FapUNIFESP (SciELO) in Revista do Instituto de Medicina Tropical de São Paulo
- Vol. 42 (6), 321-325
- https://doi.org/10.1590/s0036-46652000000600004
Abstract
Response to treatment with antimonial drugs varies considerably depending on the parasite strain involved, immune status of the patient and clinical form of the disease. Therapeutic regimens with this first line drug have been frequently modified both, in dose and duration of therapy. A regimen of 20 mg/kg/day of pentavalent antimony (Sb5+) during four weeks without an upper limit on the daily dose is currently recommended for mucosal disease ("espundia"). Side-effects with this dose are more marked in elderly patients, more commonly affected by this form of leishmaniasis. According to our experience, leishmaniasis in Rio de Janeiro responds well to antimony and, in cutaneous disease, high cure rates are obtained with 5 mg/kg/day of Sb5+ during 30 to 45-days. In this study a high rate of cure (91.4%) employing this dose was achieved in 36 patients with mild disease in this same geographic region. Side-effects were reduced and no antimony refractoriness was noted with subsequent use of larger dose in patients that failed to respond to initial schedule.Keywords
This publication has 26 references indexed in Scilit:
- A Revised Classification for Leishmania and EndotrypanumParasitology Today, 2000
- Genetic Diversity in Natural Populations of New World LeishmaniaMemórias do Instituto Oswaldo Cruz, 1998
- LeishmaniasisJournal of the American Academy of Dermatology, 1996
- Clinical healing of antimony-resistant cutaneous or mucocutaneous leishmaniasis following the combined administration of interferon-γ and pentavalent antimonial compoundsTransactions of the Royal Society of Tropical Medicine and Hygiene, 1994
- Pancreatitis Induced by Pentavalent Antimonial Agents During Treatment of LeishmaniasisClinical Infectious Diseases, 1994
- Leishmaniases of the New World: current concepts and implications for future researchClinical Microbiology Reviews, 1993
- Acute renal failure in visceral leishmaniasis treated with sodium stibogluconateTransactions of the Royal Society of Tropical Medicine and Hygiene, 1992
- Electrocardiographic alterations during treatment of mucocutaneous leishmaniasis with meglumine antimoniate and allopurinolTransactions of the Royal Society of Tropical Medicine and Hygiene, 1992
- A Review of the Geographic Distribution and Epidemiology of Leishmaniasis in the New WorldThe American Journal of Tropical Medicine and Hygiene, 1989
- Leishmania spp.: Development of pentostam-resistant clones in vitro by discontinuous drug exposureExperimental Parasitology, 1989